Roger S McIntyre, Lee Phan, Angela T H Kwan, Rodrigo B Mansur, Joshua D Rosenblat, Ziji Guo, Gia Han Le, Leanna M W Lui, Kayla M Teopiz, Felicia Ceban, Yena Lee, Julia Bailey, Ranuk Ramachandra, Joshua Di Vincenzo, Sebastian Badulescu, Hartej Gill, Pawel Drzadzewski, Mehala Subramaniapillai
Hitherto no therapeutic has received regulatory approval for the treatment of post-COVID-19 condition (PCC). Cognitive deficits, mood symptoms and significant reduction in health-related quality of life (HRQoL) are highly replicated and debilitating aspects of PCC. We sought to determine the impact of vortioxetine on the foregoing symptoms and HRQoL in persons living with PCC. An 8-week randomized, double-blind, placebo-controlled study of adults ≥ 18 years of age residing in Canada and who are experiencing symptoms of World Health Organization (WHO)-defined PCC, with a history of confirmed SARS-CoV-2 infection, was conducted...
March 1, 2024: Brain